Besides directly affecting CLL cells, Ibrutinib also exerts immunomodulatory effects on T-cells through inhibition of BTK and IL-2-inducible T-cell kinase (ITK). This evidence concerns the gene ITK and B-cell chronic lymphocytic leukemia.